Emmanuel Chautard is an expert in Oncology at Centre Jean Perrin (France). Emmanuel Chautard has authored 53 publications, the most recent in 2026. SLR score: 131 (community average: 125). How the SLR is computed.

LeadR Profile

Emmanuel Chautard Centre Jean Perrin France
131 ScienceLeadR Reputation 131
Network Map

Oncology

Subspecialties: Dermatology - Radiotherapy - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2007 - 2026

Source: PubMed

University of Clermont Auvergne

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 53

Citations

Citations: 1 156 1st author: 2 Last author: 3 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Tumor immune microenvironment predicts recurrence after radiotherapy in oropharyngeal squamous cell carcinoma.
PMID 42235796 — radiotherapy, cells, genes, lymphocytes, carcinoma, squamous cell, neoplasms, therapeutics
Radiother Oncol20260
Development and validation of a PSMA-positive triple-negative breast cancer mouse model for preclinical targeted radionuclide therapies.
PMID 41698968 — triple negative breast neoplasms, breast neoplasms, neoplasms, breast, therapeutics
Sci Rep20260
Immunomodulatory Intraperitoneal Chemotherapy with DACHPt-Loaded Biomaterial Nanoparticles in Colorectal Carcinomatosis.
PMID 41241044 — cells, nanoparticles, pharmaceutical preparations, neoplasms, drug therapy, oxaliplatin, biocompatible materials, solutions, pharmacology, therapeutics, chemotherapy
Pharmacol Res20250
Tumor sink effect on melanin-ligand [ 131I]ICF01012 in melanoma and its implications for targeted radionuclide therapy.
PMID 41003926 — melanins, melanoma, neoplasms, radiopharmaceuticals, tumor burden, therapeutics, ligands
EJNMMI Res20250
The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.
PMID 40960554 — cells, macrophages, doxorubicin, neoplasms, phenotype, chondrosarcoma, drug therapy, therapeutics, heterografts, chemotherapy
Med Oncol20250

LeadR Networks

Main global connection map